Publications by authors named "David Loach"

Claim this Profile
P
Predictors of Outcomes of Therapy-Related Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.
Ram Vasudevan Nampoothiri, Arjun Datt Law, Wilson Lam, Carol Chen, Zeyad Al-Shaibani, David Loach

Hematol Oncol Stem Cell Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of two-hour intermittent intravenous infusions of tacrolimus in the allogeneic hematopoietic stem cell transplantation unit.
Alexander Js Bacopoulos, Lina Ho, Anjie Yang, Pamela Ng, Celina Dara, David Loach

J Oncol Pharm Pract· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD.
Maria Queralt Salas, Shruti Prem, Eshetu G Atenafu, Arjun Datt Law, Wilson Lam, David Loach

Bone Marrow Transplant· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation.
Ram Vasudevan Nampoothiri, Arjun Datt Law, Wilson Lam, Carol Chen, Zeyad Al-Shaibani, David Loach

Eur J Haematol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis.
Maria Queralt Salas, Wilson Lam, Arjun Datt Law, Dennis Dong Hwan Kim, Fotios V Michelis, David Loach

Eur J Haematol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis.
Shruti Prem, David Loach, Jeffrey Lipton, Rajat Kumar, Vikas Gupta

Blood Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia.
Maria Queralt Salas, Shruti Prem, Eshetu G Atenafu, Arjun Datt Law, Wilson Lam, David Loach

Eur J Haematol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.
Fotios V Michelis, David W Hedley, Sonal Malhotra, Sue Chow, David Loach

Biol Blood Marrow Transplant· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants.
Shruti Prem, Eshetu G Atenafu, Zeyad Al-Shaibani, David Loach, Arjun Law

Eur J Haematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft--Host Disease Prophylaxis.
Maria Queralt Salas, Arjun Datt Law, Wilson Lam, Zeyad Al-Shaibani, David Loach

Clin Hematol Int· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation.
Uday Deotare, Eshetu G Atenafu, David Loach, Fotios V Michelis, Dennis Dong-Hwan Kim

Bone Marrow Transplant· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Incidence of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.
Fotios V Michelis, Rouslan Kotchetkov, Rebecca M Grunwald, Aamir Azeem, Eshetu G Atenafu, David Loach

Biol Blood Marrow Transplant· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early lymphocyte recovery at 28 d post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts.
Fotios V Michelis, Hans A Messner, David Loach, Jieun Uhm, Vikas Gupta

Eur J Haematol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.
Fotios V Michelis, Hans A Messner, Eshetu G Atenafu, Dennis D Kim, John Kuruvilla, David Loach

Biol Blood Marrow Transplant· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts.
Dong Hwan Kim, Nazir Jamal, Ronnie Saragosa, David Loach, Janice Wright

Biol Blood Marrow Transplant· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis